JPH11116482A - ホモシステイン− レベルに影響を与えるのに適する、特にホモシステインの再メチル化を助成するのに適する薬剤の製造に、天然立体異性形のテトラヒドロ葉酸塩を使用する方法 - Google Patents

ホモシステイン− レベルに影響を与えるのに適する、特にホモシステインの再メチル化を助成するのに適する薬剤の製造に、天然立体異性形のテトラヒドロ葉酸塩を使用する方法

Info

Publication number: JPH11116482A
Authority: JP; Japan
Prior art keywords: tetrahydrofolate; methyl; homocysteine; pharmaceutically compatible; formyl
Prior art date: 1997-06-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP10162405A

Other languages

English (en)

Japanese (ja)

Inventor

Hans R Mueller

ハンス・ルードルフ・ミユーラー

Martin Ulmann

マルテイン・ウルマン

Rudolf Moser

ルードルフ・モーゼル

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Eprova AG

Original Assignee

Eprova AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-06-13

Filing date

1998-06-10

Publication date

1999-04-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4210897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPH11116482(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-06-10 Application filed by Eprova AG filed Critical Eprova AG

1999-04-27 Publication of JPH11116482A publication Critical patent/JPH11116482A/ja

Status Pending legal-status Critical Current

Links

MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 title claims abstract description 29
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 title claims abstract description 24
239000005460 tetrahydrofolate Substances 0.000 title claims abstract description 24
239000003814 drug Substances 0.000 title claims description 18
238000002360 preparation method Methods 0.000 title claims description 8
230000001737 promoting effect Effects 0.000 title abstract description 3
ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 claims abstract description 23
150000003839 salts Chemical class 0.000 claims abstract description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
238000011282 treatment Methods 0.000 claims abstract description 10
QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 claims abstract description 8
VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 claims abstract description 8
201000010099 disease Diseases 0.000 claims abstract description 6
230000002265 prevention Effects 0.000 claims abstract description 6
150000001875 compounds Chemical class 0.000 claims abstract description 5
YCWUVLPMLLBDCU-STQMWFEESA-N 5-formimidoyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=N)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YCWUVLPMLLBDCU-STQMWFEESA-N 0.000 claims abstract description 4
230000007547 defect Effects 0.000 claims abstract description 4
AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 claims abstract description 3
239000013543 active substance Substances 0.000 claims description 10
229940079593 drug Drugs 0.000 claims description 9
238000000034 method Methods 0.000 claims description 4
-1 tetrahydrofolate -(6S) -tetrahydrofolate Chemical compound 0.000 claims description 4
108700019352 Methylenetetrahydrofolate reductase deficiency Proteins 0.000 claims description 3
208000000570 Methylenetetrahydrofolate reductase deficiency Diseases 0.000 claims description 3
108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 claims description 2
102000005954 Methylenetetrahydrofolate Reductase (NADPH2) Human genes 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
QYNUQALWYRSVHF-ABLWVSNPSA-N 5,10-methylenetetrahydrofolic acid Chemical compound C1N2C=3C(=O)NC(N)=NC=3NCC2CN1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-ABLWVSNPSA-N 0.000 claims 1
MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 claims 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
230000005856 abnormality Effects 0.000 abstract description 2
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003826 tablet Substances 0.000 description 20
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
239000000243 solution Substances 0.000 description 9
208000033892 Hyperhomocysteinemia Diseases 0.000 description 8
230000003225 hyperhomocysteinemia Effects 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000003708 ampul Substances 0.000 description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
229960001375 lactose Drugs 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
239000000047 product Substances 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
239000002775 capsule Substances 0.000 description 4
230000007812 deficiency Effects 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000000829 suppository Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 3
239000012154 double-distilled water Substances 0.000 description 3
229940014144 folate Drugs 0.000 description 3
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 3
235000019152 folic acid Nutrition 0.000 description 3
239000011724 folic acid Substances 0.000 description 3
229930182817 methionine Natural products 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
150000004686 pentahydrates Chemical class 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000725 suspension Substances 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
NRGONRDRXCPMIC-OLPBLLBXSA-N (2S)-2-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl]methylamino]benzoyl]amino]-4-formylpentanedioic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CC(C=O)C(O)=O)C(O)=O)C=C1 NRGONRDRXCPMIC-OLPBLLBXSA-N 0.000 description 2
RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
239000000654 additive Substances 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
JMNIIIQOMSQWJN-ZEXVLMPOSA-L calcium;(2s)-2-[[4-[[(6s)-2-amino-5-methyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@@H]1N(C=2C(=O)NC(N)=NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 JMNIIIQOMSQWJN-ZEXVLMPOSA-L 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
150000002019 disulfides Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
TZBGSHAFWLGWBO-STQMWFEESA-N (2s)-2-[[4-[[(6s)-2-amino-4-oxo-5,6,7,8-tetrahydro-1h-pteridin-6-yl]methylamino]benzoyl]amino]-5-methoxy-5-oxopentanoic acid Chemical compound C1=CC(C(=O)N[C@@H](CCC(=O)OC)C(O)=O)=CC=C1NC[C@@H]1NC(C(=O)NC(N)=N2)=C2NC1 TZBGSHAFWLGWBO-STQMWFEESA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
BBMFSGOFUHEVNP-UHFFFAOYSA-N 4-hydroxy-2-methylbenzoic acid Chemical compound CC1=CC(O)=CC=C1C(O)=O BBMFSGOFUHEVNP-UHFFFAOYSA-N 0.000 description 1
206010059245 Angiopathy Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
GFKCZHFKMGKIAQ-OLZOCXBDSA-N C([C@@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 Chemical compound C([C@@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 GFKCZHFKMGKIAQ-OLZOCXBDSA-N 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
239000002585 base Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
WUPYWCAWYJNPBS-GOHZCRCRSA-L calcium (4S)-4-[[4-[(2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C(CC[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2CNC=3N=C(N)NC(=O)C3N2)C=C1)(=O)[O-].C(CC[C@@H](C(=O)O)NC(=O)C1=CC=C(NCC2CNC=3N=C(N)NC(=O)C3N2)C=C1)(=O)[O-] WUPYWCAWYJNPBS-GOHZCRCRSA-L 0.000 description 1
UOSVKQDEUWYYOT-ZEXVLMPOSA-L calcium (4S)-4-[[4-[[(6S)-2-amino-5-formyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Ca+2].C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1.C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 UOSVKQDEUWYYOT-ZEXVLMPOSA-L 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000017858 demethylation Effects 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002449 erythroblastic effect Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
KIWQWJKWBHZMDT-UHFFFAOYSA-N homocysteine thiolactone Chemical compound NC1CCSC1=O KIWQWJKWBHZMDT-UHFFFAOYSA-N 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
235000003715 nutritional status Nutrition 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
VLKFYBLZIAZYPW-FXMYHANSSA-M sodium (4S)-4-[[4-[[(6S)-2-amino-4-oxo-5,6,7,8-tetrahydro-3H-pteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Na+].C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 VLKFYBLZIAZYPW-FXMYHANSSA-M 0.000 description 1
FCDNBNJHYOMJIQ-QNTKWALQSA-M sodium (4S)-4-[[4-[[(6S)-2-amino-5-methyl-4-oxo-3,6,7,8-tetrahydropteridin-6-yl]methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound [Na+].CN1C=2C(NC(=NC=2NC[C@@H]1CNC1=CC=C(C(N[C@@H](CCC(=O)[O-])C(=O)O)=O)C=C1)N)=O FCDNBNJHYOMJIQ-QNTKWALQSA-M 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000013589 supplement Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
150000003722 vitamin derivatives Chemical class 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Nutrition Science (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Liquid Crystal Substances (AREA)

JP10162405A 1997-06-13 1998-06-10 ホモシステイン− レベルに影響を与えるのに適する、特にホモシステインの再メチル化を助成するのに適する薬剤の製造に、天然立体異性形のテトラヒドロ葉酸塩を使用する方法 Pending JPH11116482A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH01456/97A CH693255A5 (de)	1997-06-13	1997-06-13	Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
CH1456/97		1997-06-13

Publications (1)

Publication Number	Publication Date
JPH11116482A true JPH11116482A (ja)	1999-04-27

Family

ID=4210897

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP10162405A Pending JPH11116482A (ja)	1997-06-13	1998-06-10	ホモシステイン− レベルに影響を与えるのに適する、特にホモシステインの再メチル化を助成するのに適する薬剤の製造に、天然立体異性形のテトラヒドロ葉酸塩を使用する方法

Country Status (15)

Country	Link
US (1)	US6011040A (es)
EP (2)	EP0898965B9 (es)
JP (1)	JPH11116482A (es)
CN (1)	CN102151271A (es)
AT (2)	ATE321555T1 (es)
AU (1)	AU739544B2 (es)
CA (1)	CA2240571C (es)
CH (1)	CH693255A5 (es)
DE (1)	DE59813465D1 (es)
DK (2)	DK1685840T3 (es)
ES (2)	ES2376472T3 (es)
PT (2)	PT1685840E (es)
RU (1)	RU2226099C2 (es)
TW (1)	TW474812B (es)
ZA (1)	ZA985129B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008540482A (ja) *	2005-05-13	2008-11-20	バイエル・シエーリング・ファーマアクチエンゲゼルシャフト	プロゲストゲン及び／又はエストロゲン及び５−メチル−（６ｓ）−テトラヒドロフォレートを含んで成る医薬組成物
JP2020512383A (ja) *	2017-03-31	2020-04-23	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	５−メチル−（６ｓ）−テトラヒドロ葉酸の結晶性ナトリウム塩
JP2020515614A (ja) *	2017-03-31	2020-05-28	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	５−メチル−（６ｓ）−テトラヒドロ葉酸の結晶性ナトリウム塩

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3602141B2 (ja)	1996-01-31	2004-12-15	サウス、アラバマ、メディカル、サイエンス、ファウンデーション	還元されたフォレートの天然異性体を含む食品およびビタミン製剤
MXPA01000973A (es) *	1998-08-03	2002-06-04	Epigenesis Pharmaceuticals Inc	Un nuevo agente analgesico antiinflamatorio y de cicatrizacion de heridas.
DE10062401A1 (de) *	2000-12-14	2002-06-20	Beiersdorf Ag	Verwendung von Folsäure und/oder deren Derivaten zur Herstellung kosmetischer oder dermatologischer Zubereitungen zur Prophylaxe von Schäden an der hauteigenen DNA und/oder zur Reparatur bereits eingetretener Schäden an der hauteigenen DNA
WO2002083151A2 (en) *	2000-12-14	2002-10-24	Tufts University	Compositions and methods for treating an arthritic condition
FR2828076B1 (fr) *	2001-07-31	2003-11-07	Olivier Laroche	Banquette pour musicien
US8173618B2 (en) *	2003-07-25	2012-05-08	University Of Massachusetts	Formulations for reducing neuronal degeneration
SE0303526D0 (sv) *	2003-12-22	2003-12-22	Biofol Ab	Chemotherapeutic agents
PL3138566T3 (pl)	2003-11-17	2022-03-07	Biomarin Pharmaceutical Inc.	Leczenie fenyloketonurii z użyciem bh4
EP2436379A1 (en)	2004-11-17	2012-04-04	BioMarin Pharmaceutical Inc.	Stable tablet formulation
EP1819340A2 (en) *	2004-12-08	2007-08-22	Biomarin Pharmaceutical Inc.	Methods and compositions for the treatment of pulmonary hypertension of the newborn
US7687473B2 (en) *	2005-01-07	2010-03-30	Health Research, Inc.	5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
WO2006119589A2 (en) *	2005-05-11	2006-11-16	Ramaekers, Vincent	Prevention and therapy of cerebral folate deficiency
US20060293295A1 (en) *	2005-05-13	2006-12-28	Kai Strothmann	Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
DE102005023301B4 (de) *	2005-05-13	2012-05-31	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
AU2012227235B2 (en) *	2005-05-13	2015-06-11	Bayer Intellectual Property Gmbh	Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
RU2312674C2 (ru) *	2005-12-28	2007-12-20	Юрий Антонович Кошелев	Биологически активная добавка "витабс кардио" для профилактики сердечно-сосудистых заболеваний
CN101489563A (zh)	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
US8617597B2 (en)	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
EP2037935A1 (de) *	2006-07-06	2009-03-25	Bayer Schering Pharma AG	Pharmazeutische zubereitung zur kontrazeption und zur verminderung des risikos angeborener fehlbildungen
US20080064702A1 (en) *	2006-09-08	2008-03-13	Charalambos Antoniades	Use of folates for the prevention and treatment of vascular diseases
PL2139485T3 (pl)	2007-04-11	2013-03-29	Biomarin Pharm Inc	Metoda podawania tetrahydrobiopteryny, powiązane kompozycje i sposoby pomiaru
EP2027855A1 (de)	2007-08-24	2009-02-25	Bayer Schering Pharma AG	Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
US20090060997A1 (en) *	2007-08-27	2009-03-05	Christian Seitz	Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
US8597640B2 (en) *	2007-10-31	2013-12-03	University Of Massachusetts Lowell	Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
BRPI0908477A2 (pt) *	2008-02-13	2018-03-27	Bayer Schering Pharma Ag	sistema de distribuição de medicamento contendo estradiol
US20110171134A1 (en) *	2008-06-25	2011-07-14	Iskandar Bermans J	(6s)-5-methyltetrahydrofolic acid for therapy of tissue injury
CA2804265C (en)	2009-07-10	2019-02-19	Linzy O. Scott, Iii	Methods and compositions for treating thyroid-related medical conditions with reduced folates
UY32836A (es)	2009-08-12	2011-03-31	Bayer Schering Pharma Ag	Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
WO2011100550A2 (en)	2010-02-12	2011-08-18	Alexander Vuckovic, M.D., Llc	Compositions and methods for treating depression
US9216178B2 (en)	2011-11-02	2015-12-22	Biomarin Pharmaceutical Inc.	Dry blend formulation of tetrahydrobiopterin
US20160053281A1 (en)	2013-08-15	2016-02-25	The University Court Of The University Of Edinburgh	Enhanced Expression Of RNA Vectors
WO2016185413A1 (en)	2015-05-20	2016-11-24	Nestec S.A.	Modified release formulations
AU2017397463B2 (en)	2016-11-03	2022-01-06	HedoniaUSA, Inc.	Compositions and methods for treating depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1350160A (en) *	1971-06-29	1974-04-18	Foremost Mckesson	Pharmaceutical compositions
IT1229203B (it) *	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE69027585T2 (de) *	1989-12-11	1997-01-16	American Cyanamid Co	Verfahren zur Herstellung von optisch reinen Diastereoisomeren von Tetrahydrofolatverbindungen
CA2082811C (en) *	1990-05-11	2004-11-16	Colin P. Spears	5,10-methylene-tetrahydrofolate as a modulator of a chemotherapeutic agent
CH682664A5 (en) *	1991-10-15	1993-10-29	Eprova Ag	Stable salts of 5,10-methylene tetrahydrofolate.
CH684644A5 (de) *	1992-07-13	1994-11-15	Eprova Ag	5,10-Methylentetrahydrofolsäure-Cyclodextrin-Einschlussverbindungen.
ZA936723B (en) *	1992-09-14	1995-08-14	Vesta Med Pty Ltd	Pharmaceutical preparations for lowering homocysteine levels
CH689831A5 (de) *	1995-11-07	1999-12-15	Eprova Ag	Stabile kristalline Tetrahydrofolsaeure-Salze.
JP3602141B2 (ja) *	1996-01-31	2004-12-15	サウス、アラバマ、メディカル、サイエンス、ファウンデーション	還元されたフォレートの天然異性体を含む食品およびビタミン製剤
US6008221A (en) *	1996-11-06	1999-12-28	Bristol-Myers Squibb Company	Method for treating Alzheimer's disease with folic acid

1997
- 1997-06-13 CH CH01456/97A patent/CH693255A5/de not_active IP Right Cessation
1998
- 1998-06-05 AT AT98110302T patent/ATE321555T1/de active
- 1998-06-05 DK DK06006085.2T patent/DK1685840T3/da active
- 1998-06-05 PT PT06006085T patent/PT1685840E/pt unknown
- 1998-06-05 PT PT98110302T patent/PT898965E/pt unknown
- 1998-06-05 EP EP98110302A patent/EP0898965B9/de not_active Expired - Lifetime
- 1998-06-05 EP EP06006085A patent/EP1685840B1/de not_active Expired - Lifetime
- 1998-06-05 AT AT06006085T patent/ATE538793T1/de active
- 1998-06-05 ES ES06006085T patent/ES2376472T3/es not_active Expired - Lifetime
- 1998-06-05 DE DE59813465T patent/DE59813465D1/de not_active Expired - Lifetime
- 1998-06-05 DK DK98110302T patent/DK0898965T3/da active
- 1998-06-05 ES ES98110302T patent/ES2262202T3/es not_active Expired - Lifetime
- 1998-06-08 TW TW087109073A patent/TW474812B/zh not_active IP Right Cessation
- 1998-06-10 JP JP10162405A patent/JPH11116482A/ja active Pending
- 1998-06-10 RU RU98111617/15A patent/RU2226099C2/ru not_active IP Right Cessation
- 1998-06-11 AU AU70079/98A patent/AU739544B2/en not_active Ceased
- 1998-06-11 US US09/095,572 patent/US6011040A/en not_active Expired - Lifetime
- 1998-06-12 CN CN2011100469951A patent/CN102151271A/zh active Pending
- 1998-06-12 CA CA002240571A patent/CA2240571C/en not_active Expired - Lifetime
- 1998-06-12 ZA ZA985129A patent/ZA985129B/xx unknown

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2008540482A (ja) *	2005-05-13	2008-11-20	バイエル・シエーリング・ファーマアクチエンゲゼルシャフト	プロゲストゲン及び／又はエストロゲン及び５−メチル−（６ｓ）−テトラヒドロフォレートを含んで成る医薬組成物
JP2020512383A (ja) *	2017-03-31	2020-04-23	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	５−メチル−（６ｓ）−テトラヒドロ葉酸の結晶性ナトリウム塩
JP2020515614A (ja) *	2017-03-31	2020-05-28	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	５−メチル−（６ｓ）−テトラヒドロ葉酸の結晶性ナトリウム塩
US11377448B2 (en)	2017-03-31	2022-07-05	Merck Patent Gmbh	Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid

Also Published As

Publication number	Publication date
AU739544B2 (en)	2001-10-18
DE59813465D1 (de)	2006-05-18
ZA985129B (en)	1998-12-14
PT898965E (pt)	2006-08-31
CN102151271A (zh)	2011-08-17
ES2262202T3 (es)	2006-11-16
AU7007998A (en)	1998-12-17
PT1685840E (pt)	2012-02-09
US6011040A (en)	2000-01-04
CA2240571C (en)	2006-08-08
EP1685840B1 (de)	2011-12-28
CA2240571A1 (en)	1998-12-13
CH693255A5 (de)	2003-05-15
ATE538793T1 (de)	2012-01-15
EP0898965A2 (de)	1999-03-03
TW474812B (en)	2002-02-01
EP1685840A3 (de)	2010-06-02
ATE321555T1 (de)	2006-04-15
EP0898965A3 (de)	2000-11-15
ES2376472T3 (es)	2012-03-14
DK0898965T3 (da)	2006-07-31
RU2226099C2 (ru)	2004-03-27
EP0898965B9 (de)	2006-08-09
DK1685840T3 (da)	2012-04-10
EP1685840A2 (de)	2006-08-02
EP0898965B1 (de)	2006-03-29

Legal Events

Date	Code	Title	Description
1998-08-25	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 19980717
1998-09-29	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 19980820
2004-06-30	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040629
2008-01-24	A977	Report on retrieval	Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20080124
2008-02-12	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080212
2008-05-10	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080509
2008-05-15	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080514
2008-08-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080812
2008-09-30	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930
2008-12-25	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081224
2009-01-06	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090105
2009-04-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090327
2009-10-27	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091027
2010-05-28	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100527

Publication	Publication Date	Title
JPH11116482A (ja)	1999-04-27	ホモシステイン− レベルに影響を与えるのに適する、特にホモシステインの再メチル化を助成するのに適する薬剤の製造に、天然立体異性形のテトラヒドロ葉酸塩を使用する方法
EP0209689B1 (en)	1992-03-11	Use of tetrahydrobiopterins in the preparation of a medicament for the treatment of infantile autism
CA2477101C (en)	2012-10-30	Use of folates for preventing and treating inflammation and diseases associated with inflammation
US20060134226A1 (en)	2006-06-22	Compositions useful to treat ocular neovascular diseases and macular degeneration
KR20020025088A (ko)	2002-04-03	필수지방산 및 호모시스테인-저하제를 포함하는 약제학적및 영양학적 조성물
JPH05194229A (ja)	1993-08-03	プテリン誘導体からなる精神疾患症状の治療剤
JP2002528507A (ja)	2002-09-03	神経疾患および病態心理学的疾患の治療および予防用の組成物
US20160008300A1 (en)	2016-01-14	Compositions and Methods for Nutritional Supplementation
US20130004570A1 (en)	2013-01-03	Nutritional supplement for use under physiologically stressful conditions
AU2001297789B9 (en)	2008-07-10	Compositions and methods for treating an arthritic condition
US20020010148A1 (en)	2002-01-24	Oral combinations of hydroxocobalamin and folic acid
AU2001297789A1 (en)	2003-04-17	Compositions and methods for treating an arthritic condition
US20020187956A1 (en)	2002-12-12	Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
JPWO2020043840A5 (es)	2022-10-24
MXPA98004683A (es)	1999-09-20	El uso de tetrahidrofolatos en forma estereoisomerica natural para la produccion de una preparacionfarmaceutica adecuada para influenciar el nivel de homocisteina, particularmente para ayudar en la remetilacion de homocisteina
HK1156850A (en)	2012-06-22	The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation
JP4896531B2 (ja)	2012-03-14	血中ＣｏＱ１０量を増加させる医薬組成物
WO2025031946A1 (en)	2025-02-13	Liquid formulations of folates
WO2005109175A2 (en)	2005-11-17	Vitamin compositions and treatment methods for metabolic diseases and nutrient deficiencies
WO2026017709A1 (en)	2026-01-22	Folate for use in methods of reducing severity, incidence or risk in lymphedema or in glymphatic- related neurodevelopmental disorders
WO2025203055A1 (en)	2025-10-02	Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof
WO2005032592A1 (ja)	2005-04-14	催眠剤組成物
Shinnick et al.	1999	Coronary artery disease and homocysteine: a case study
JPH11116501A (ja)	1999-04-27	骨吸収関連疾患治療剤